Diagnosing and treating HIV-associated sensory neuropathy: a global perspective

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Lipkin WI, Parry G, Kiprov D, Abrams D. Inflammatory neuropathy in homosexual men with lymphadenopathy. Neurology 35(10), 1479–1483 (1985).
  Medline CASGoogle Scholar
• 2 Cherry CL, Kamerman PR, Bennett DLH, Rice ASC. HIV-associated sensory neuropathy: still a problem in the post-stavudine era? Future Virol. 7(9), 848–854 (2012).
  Google Scholar
• 3 Cherry CL, Affandi JS, Brew BJ et al. Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV. Neurology 74(19), 1538–1542 (2010).
  Medline CASGoogle Scholar
• 4 Smyth K, Affandi JS, Mcarthur JC et al. Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993–2006. HIV Med. 8(6), 367–373 (2007).
  Medline CASGoogle Scholar
• 5 Wadley AL, Cherry CL, Price P, Kamerman PR. HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans. J. Pain Symptom Manage. 41(4), 700–706 (2011).
  MedlineGoogle Scholar
• 6 Wright E, Brew B, Arayawichanont A et al. Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region. Neurology 71(1), 50–56 (2008).
  Medline CASGoogle Scholar
• 7 Maritz J, Benatar M, Dave JA et al. HIV neuropathy in South Africans: frequency, characteristics, and risk factors. Muscle Nerve 41(5), 599–606 (2010).
  MedlineGoogle Scholar
• 8 Shurie JS, Deribew A. Assessment of the prevalence of distal symmetrical polyneuropathy and its risk factors among HAART-treated and untreated HIV infected individuals. Ethiop. Med. J. 48(2), 85–93 (2010).
  MedlineGoogle Scholar
• 9 Cherry CL, Affandi JS, Imran D et al. Age and height predict neuropathy risk in patients with HIV prescribed stavudine. Neurology 73(4), 315–320 (2009).
  Medline CASGoogle Scholar
• 10 Farrant L, Gwyther L, Dinat N, Mmoledi K, Hatta N, Harding R. Maintaining wellbeing for South Africans receiving ART: the burden of pain and symptoms is greater with longer ART exposure. S. Afr. Med. J. 104(2), 119–123 (2014).
  Medline CASGoogle Scholar
• 11 Phillips TJ, Brown M, Ramirez JD et al. Sensory, psychological, and metabolic dysfunction in HIV-associated peripheral neuropathy: a cross-sectional deep profiling study. Pain 155(9), 1846–1860 (2014).
  MedlineGoogle Scholar
• 12 Mann R, Sadosky A, Schaefer C et al. Burden of HIV-related neuropathic Pain in the United States. J. Int. Assoc. Provid. AIDS Care doi:10.1177/2325957415592474 (2015) (Epub ahead of print).
  MedlineGoogle Scholar
• 13 Ellis RJ, Rosario D, Clifford DB et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch. Neurol. 67(5), 552–558 (2010). •• Perhaps the most convincing epidemiologic data demonstrating the continuing high prevalence of HIV-associated sensory neuropathy (HIV-SN) in populations never exposed to known neurotoxic antiretroviral medications.
  MedlineGoogle Scholar
• 14 Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS ONE 5(12), e14433 (2010). • A systematic review of randomized analgesic trials for HIV-SN.
  Medline CASGoogle Scholar
• 15 Global Health Observatory Data, HIV/AIDS. www.who.int/gho/hiv/en/.
  Google Scholar
• 16 Mcarthur J, Smith B. Neurologic complications and considerations in HIV-infected persons. Curr. Infect. Dis. Rep. 15(1), 61–66 (2013).
  MedlineGoogle Scholar
• 17 Evans SR, Lee AJ, Ellis RJ et al. HIV peripheral neuropathy progression: protection with glucose-lowering drugs? J. Neurovirol. 18(5), 428–433 (2012).
  Medline CASGoogle Scholar
• 18 Cherry CL, Wesselingh SL, Lal L, Mcarthur JC. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology 65(11), 1778–1781 (2005).
  MedlineGoogle Scholar
• 19 Kandiah PA, Atadzhanov M, Kvalsund MP, Birbeck GL. Evaluating the diagnostic capacity of a single-question neuropathy screen (SQNS) in HIV positive Zambian adults. J. Neurol. Neurosurg. Psychiatry 81(12), 1380–1381 (2010).
  MedlineGoogle Scholar
• 20 Robinson-Papp J, Morgello S, Vaida F et al. Association of self-reported painful symptoms with clinical and neurophysiologic signs in HIV-associated sensory neuropathy. Pain 151(3), 732–736 (2010).
  Medline CASGoogle Scholar
• 21 Treede RD, Jensen TS, Campbell JN et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 70(18), 1630–1635 (2008).
  Medline CASGoogle Scholar
• 22 Kamerman PR, Mitchell D. Current perspectives on HIV-related pain and its management: insights from sub-Saharan Africa. Pain Manag. 1(6), 587–596 (2011).
  Google Scholar
• 23 Happe S, Kundmuller L, Reichelt D, Husstedt IW, Evers S. Comorbidity of restless legs syndrome and HIV infection. J. Neurol. 254(10), 1401–1406 (2007).
  Medline CASGoogle Scholar
• 24 Keswani SC, Pardo CA, Cherry CL, Hoke A, McArthur JC. HIV-associated sensory neuropathies. AIDS 16(16), 2105–2117 (2002).
  MedlineGoogle Scholar
• 25 Tagliati M, Grinnell J, Godbold J, Simpson DM. Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Arch. Neurol. 56(1), 84–89 (1999).
  Medline CASGoogle Scholar
• 26 Bouhassira D, Attal N, Willer JC, Brasseur L. Painful and painless peripheral sensory neuropathies due to HIV infection: a comparison using quantitative sensory evaluation. Pain 80(1–2), 265–272 (1999).
  Medline CASGoogle Scholar
• 27 Huengsberg M, Winer JB, Ross JD, Shahmanesh M. Thermosensory threshold: a sensitive test of HIV associated peripheral neuropathy? J. Neurovirol. 4(4), 433–437 (1998).
  Medline CASGoogle Scholar
• 28 Holland NR, Stocks A, Hauer P, Cornblath DR, Griffin JW, Mcarthur JC. Intraepidermal nerve fiber density in patients with painful sensory neuropathy. Neurology 48(3), 708–711 (1997).
  Medline CASGoogle Scholar
• 29 Mcarthur JC, Stocks EA, Hauer P, Cornblath DR, Griffin JW. Epidermal nerve fiber density: normative reference range and diagnostic efficiency. Arch. Neurol. 55(12), 1513–1520 (1998).
  Medline CASGoogle Scholar
• 30 Mccarthy BG, Hsieh ST, Stocks A et al. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 45(10), 1848–1855 (1995).
  Medline CASGoogle Scholar
• 31 Cherry CL, Skolasky RL, Lal L et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology 66(6), 867–873 (2006).
  Medline CASGoogle Scholar
• 32 Zhou L, Kitch DW, Evans SR et al. Correlates of epidermal nerve fiber densities in HIV-associated distal sensory polyneuropathy. Neurology 68(24), 2113–2119 (2007).
  Medline CASGoogle Scholar
• 33 Skopelitis E, Aroni K, Kontos AN et al. Early detection of subclinical HIV sensory polyneuropathy using intraepidermal nerve fibre density quantification: association with HIV stage and surrogate markers. Int. J. STD AIDS 18(12), 856–860 (2007).
  Medline CASGoogle Scholar
• 34 Shikuma C, Gerschenson M, Ananworanich J et al. Determinants of epidermal nerve fibre density in antiretroviral-naive HIV-infected individuals. HIV Med. 13(10), 602–608 (2012).
  MedlineGoogle Scholar
• 35 Shikuma CM, Mcarthur JC, Ebenezer GJ et al. Ethnic differences in epidermal nerve fiber density. Muscle Nerve 48(3), 462–464 (2013).
  MedlineGoogle Scholar
• 36 Cettomai D, Kwasa J, Birbeck GL, Price RW, Bukusi EA, Meyer AC. Training needs and evaluation of a neuro-HIV training module for non-physician healthcare workers in western Kenya. J. Neurol. Sci. 307(1–2), 92–96 (2011).
  MedlineGoogle Scholar
• 37 McArthur JC, Yiannoutsos C, Simpson DM et al. A Phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 54(5), 1080–1088 (2000).
  Medline CASGoogle Scholar
• 38 Finnerup NB, Attal N, Haroutounian S et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 14(2), 162–173 (2015). •• A useful summary of the data (and its limitations) relating to pharmacologic treatment of neuropathic pain in general.
  Medline CASGoogle Scholar
• 39 Abrams DI, Jay CA, Shade SB et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68(7), 515–521 (2007).
  Medline CASGoogle Scholar
• 40 Ellis RJ, Toperoff W, Vaida F et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 34(3), 672–680 (2009).
  Medline CASGoogle Scholar
• 41 Clifford DB, Simpson DM, Brown S et al. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J. Acquir. Immune Defic. Syndr. 59(2), 126–133 (2012).
  Medline CASGoogle Scholar
• 42 Derry S, Sven-Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst. Rev. 2, CD007393 (2013).
  Google Scholar
• 43 Dinat N, Marinda E, Moch S, Rice AS, Kamerman PR. Randomized, double-blind, crossover trial of amitriptyline for analgesia in painful HIV-associated sensory neuropathy. PLoS ONE 10(5), e0126297 (2015).
  MedlineGoogle Scholar
• 44 Shlay JC, Chaloner K, Max MB et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 280(18), 1590–1595 (1998).
  Medline CASGoogle Scholar
• 45 Kieburtz K, Simpson D, Yiannoutsos C et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology 51(6), 1682–1688 (1998).
  Medline CASGoogle Scholar
• 46 Hahn K, Arendt G, Braun JS et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J. Neurol. 251(10), 1260–1266 (2004).
  Medline CASGoogle Scholar
• 47 Simpson DM, Rice AS, Emir B et al. A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy. Pain 155(10), 1943–1954 (2014).
  Medline CASGoogle Scholar
• 48 Simpson DM, Schifitto G, Clifford DB et al. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology 74(5), 413–420 (2010).
  Medline CASGoogle Scholar
• 49 Simpson DM, Mcarthur JC, Olney R et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 60(9), 1508–1514 (2003).
  Medline CASGoogle Scholar
• 50 Simpson DM, Olney R, Mcarthur JC, Khan A, Godbold J, Ebel-Frommer K. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 54(11), 2115–2119 (2000).
  Medline CASGoogle Scholar
• 51 Harrison T, Miyahara S, Lee A et al. Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies. Pain Med. 14(7), 1039–1047 (2013).
  MedlineGoogle Scholar
• 52 Kamerman PR, Wadley AL, Davis KD et al. World Health Organization essential medicines lists: where are the drugs to treat neuropathic pain? Pain 156(5), 793–797 (2015).
  MedlineGoogle Scholar
• 53 Cepeda MS, Berlin JA, Gao CY, Wiegand F, Wada DR. Placebo response changes depending on the neuropathic pain syndrome: results of a systematic review and meta-analysis. Pain Med. 13(4), 575–595 (2012). •• This paper analyses the placebo response in analgesic trials in different neuropathic pain states, including HIV-SN.
  MedlineGoogle Scholar
• 54 Tuttle AH, Tohyama S, Ramsay T et al. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain doi:10.1097/j.pain.0000000000000333 (2015) (Epub ahead of print). • An interesting and current analysis of how increasing placebo responses, primarily in the USA, may be impacting neuropathic pain trials.
  MedlineGoogle Scholar
• 55 Attal N, Bouhassira D, Baron R et al. Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome? Eur. J. Pain 15(5), 441–443 (2011).
  MedlineGoogle Scholar
• 56 Baron R, Forster M, Binder A. Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach. Lancet Neurol. 11(11), 999–1005 (2012).
  MedlineGoogle Scholar
• 57 Freeman R, Baron R, Bouhassira D, Cabrera J, Emir B. Sensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs. Pain 155(2), 367–376 (2014).
  MedlineGoogle Scholar
• 58 Maier C, Baron R, Tolle TR et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain 150(3), 439–450 (2010).
  Medline CASGoogle Scholar
• 59 Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann. Neurol. 64(3), 274–283 (2008).
  MedlineGoogle Scholar
• 60 Attal N, Rouaud J, Brasseur L, Chauvin M, Bouhassira D. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology 62(2), 218–225 (2004).
  Medline CASGoogle Scholar
• 61 Polydefkis M, Raja SN. What can we learn from failed neuropathic pain trials? Neurology 70(4), 250–251 (2008).
  MedlineGoogle Scholar
• 62 Pillay P, Wadley AL, Cherry CL, Karstaedt AS, Kamerman PR. Pharmacological treatment of painful HIV-associated sensory neuropathy. S. Afr. Med. J. 105(9), 769–772 (2015).
  Medline CASGoogle Scholar
• 63 Dorfman D, George MC, Schnur J, Simpson DM, Davidson G, Montgomery G. Hypnosis for treatment of HIV neuropathic pain: a preliminary report. Pain Med. 14(7), 1048–1056 (2013). • This small pilot study provides the clearest published evidence for the possible efficacy of nondrug strategies for managing HIV-SN pain.
  MedlineGoogle Scholar
• 64 Langenfeld MC, Cipani E, Borckardt JJ. Hypnosis for the control of HIV/AIDS-related pain. Int. J. Clin. Exp. Hypn. 50(2), 170–188 (2002).
  MedlineGoogle Scholar
• 65 Gonzalez-Garcia M, Ferrer MJ, Borras X et al. Effectiveness of mindfulness-based cognitive therapy on the quality of life, emotional status, and CD4 cell count of patients aging with HIV infection. AIDS Behav. 18(4), 676–685 (2014).
  MedlineGoogle Scholar
• 66 Riley KE, Kalichman S. Mindfulness-based stress reduction for people living with HIV/AIDS: preliminary review of intervention trial methodologies and findings. Health Psychol. Rev. 9(2), 224–243 (2015).
  MedlineGoogle Scholar
• 67 Seyedalinaghi S, Jam S, Foroughi M et al. Randomized controlled trial of mindfulness-based stress reduction delivered to human immunodeficiency virus-positive patients in Iran: effects on CD4⁺ T lymphocyte count and medical and psychological symptoms. Psychosom. Med. 74(6), 620–627 (2012).
  MedlineGoogle Scholar
• 68 Meize-Grochowski R, Shuster G, Boursaw B et al. Mindfulness meditation in older adults with postherpetic neuralgia: a randomized controlled pilot study. Geriatr. Nurs. 36(2), 154–160 (2015).
  MedlineGoogle Scholar
• 69 Nicholas PK, Kemppainen JK, Canaval GE et al. Symptom management and self-care for peripheral neuropathy in HIV/AIDS. AIDS Care 19(2), 179–189 (2007).
  Medline CASGoogle Scholar
• 70 Merlin JS, Cen L, Praestgaard A et al. Pain and physical and psychological symptoms in ambulatory HIV patients in the current treatment era. J. Pain Symptom Manage. 43(3), 638–645 (2012).
  MedlineGoogle Scholar
• 71 Lucey BP, Clifford DB, Creighton J, Edwards RR, McArthur JC, Haythornthwaite J. Relationship of depression and catastrophizing to pain, disability, and medication adherence in patients with HIV-associated sensory neuropathy. AIDS Care 23(8), 921–928 (2011).
  MedlineGoogle Scholar
• 72 Keltner JR, Vaida F, Ellis RJ et al. Health-related quality of life ‘well-being’ in HIV distal neuropathic pain is more strongly associated with depression severity than with pain intensity. Psychosomatics 53(4), 380–386 (2012).
  MedlineGoogle Scholar
• 73 Trafton JA, Sorrell JT, Holodniy M et al. Outcomes associated with a cognitive–behavioral chronic pain management program implemented in three public HIV primary care clinics. J. Behav. Health Serv. Res. 39(2), 158–173 (2012).
  MedlineGoogle Scholar
• 74 Huggins JL, Bonn-Miller MO, Oser ML, Sorrell JT, Trafton JA. Pain anxiety, acceptance, and outcomes among individuals with HIV and chronic pain: a preliminary investigation. Behav. Res. Ther. 50(1), 72–78 (2012).
  MedlineGoogle Scholar
• 75 Nicholas PK, Voss JG, Corless IB et al. Unhealthy behaviours for self-management of HIV-related peripheral neuropathy. AIDS Care 19(10), 1266–1273 (2007).
  Medline CASGoogle Scholar
• 76 Nicholas PK, Voss J, Wantland D et al. Prevalence, self-care behaviors, and self-care activities for peripheral neuropathy symptoms of HIV/AIDS. Nurs. Health Sci. 12(1), 119–126 (2010).
  MedlineGoogle Scholar
• 77 Merlin JS, Walcott M, Kerns R, Bair MJ, Burgio KL, Turan JM. Pain self-management in HIV-infected individuals with chronic pain: a qualitative study. Pain Med. 16(4), 706–714 (2015).
  MedlineGoogle Scholar
• 78 Fillipas S, Oldmeadow LB, Bailey MJ, Cherry CL. A six-month, supervised, aerobic and resistance exercise program improves self-efficacy in people with human immunodeficiency virus: a randomised controlled trial. Aust. J. Physiother. 52(3), 185–190 (2006).
  MedlineGoogle Scholar
• 79 Neidig JL, Smith BA, Brashers DE. Aerobic exercise training for depressive symptom management in adults living with HIV infection. J. Assoc. Nurses AIDS Care 14(2), 30–40 (2003).
  MedlineGoogle Scholar
• 80 O'Brien K, Nixon S, Tynan AM, Glazier R. Aerobic exercise interventions for adults living with HIV/AIDS. Cochrane Database Syst. Rev. (8), CD001796 (2010).
  MedlineGoogle Scholar
• 81 Parker R, Jelsma J, Stein DJ. Managing pain in women living with HIV/AIDS: a randomised controlled trial testing the effect of a six-week peer-led exercise and education intervention. J. Nerv. Ment. Dis. (2016) (In Press).
  MedlineGoogle Scholar
• 82 Mphahlele NR, Kamerman PR, Mitchell D. Progression of pain in ambulatory HIV-positive South Africans. Pain Manag. Nurs. 16(1), e1–e8 (2015).
  MedlineGoogle Scholar
• 83 Kaptchuk TJ, Kelley JM, Conboy LA et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 336(7651), 999–1003 (2008).
  MedlineGoogle Scholar
• 84 Ferreira PH, Ferreira ML, Maher CG, Refshauge KM, Latimer J, Adams RD. The therapeutic alliance between clinicians and patients predicts outcome in chronic low back pain. Phys. Ther. 93(4), 470–478 (2013).
  MedlineGoogle Scholar
• 85 Johnson MO, Chesney MA, Goldstein RB et al. Positive provider interactions, adherence self-efficacy, and adherence to antiretroviral medications among HIV-infected adults: a mediation model. AIDS Patient Care STDS 20(4), 258–268 (2006).
  MedlineGoogle Scholar
• 86 Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N. Engl. J. Med. 373(9), 795–807 (2015).
  MedlineGoogle Scholar
• 87 Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.
  Google Scholar
• 88 Van Sighem AI, Gras LA, Reiss P, Brinkman K, De Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 24(10), 1527–1535 (2010).
  MedlineGoogle Scholar
• 89 Mills EJ, Bakanda C, Birungi J et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann. Intern. Med. 155(4), 209–216 (2011).
  MedlineGoogle Scholar
• 90 Kamerman PR, Wadley AL, Cherry CL. HIV-associated sensory neuropathy: risk factors and genetics. Curr. Pain Headache Rep. 16(3), 226–236 (2012). •• A recent review of what is known about risk factors that predispose an individual to developing HIV-SN.
  MedlineGoogle Scholar
• 91 Kamerman PR, Moss PJ, Weber J, Wallace VC, Rice AS, Huang W. Pathogenesis of HIV-associated sensory neuropathy: evidence from in vivo and in vitro experimental models. J. Peripher. Nerv. Syst. 17(1), 19–31 (2012).
  Medline CASGoogle Scholar